Does LAROTRECTINIB Cause Off label use? 31 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 31 reports of Off label use have been filed in association with LAROTRECTINIB (VITRAKVI). This represents 3.9% of all adverse event reports for LAROTRECTINIB.
31
Reports of Off label use with LAROTRECTINIB
3.9%
of all LAROTRECTINIB reports
7
Deaths
4
Hospitalizations
How Dangerous Is Off label use From LAROTRECTINIB?
Of the 31 reports, 7 (22.6%) resulted in death, 4 (12.9%) required hospitalization.
Is Off label use Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for LAROTRECTINIB. However, 31 reports have been filed with the FAERS database.
What Other Side Effects Does LAROTRECTINIB Cause?
Fatigue (56)
Drug ineffective (52)
Dizziness (50)
Death (48)
Pain (42)
Neuropathy peripheral (39)
Nausea (32)
Disease progression (27)
Malignant neoplasm progression (23)
Myalgia (23)
What Other Drugs Cause Off label use?
RITUXIMAB (39,751)
INFLIXIMAB (34,801)
DENOSUMAB (34,612)
METHOTREXATE (24,020)
VEDOLIZUMAB (21,017)
ETANERCEPT (20,178)
TOCILIZUMAB (18,256)
PREDNISONE (17,867)
LENALIDOMIDE (17,017)
ADALIMUMAB (16,417)
Which LAROTRECTINIB Alternatives Have Lower Off label use Risk?
LAROTRECTINIB vs LASILIX
LAROTRECTINIB vs LASIX
LAROTRECTINIB vs LASMIDITAN
LAROTRECTINIB vs LATANOPROST
LAROTRECTINIB vs LATANOPROSTENE BUNOD